doi:10.1007/s12250-015-3605-4

[1]
Fengling Luo, Tielong Chen, Jun Liu, Xihui Shen, Yinnan Zhao, Rongge Yang, Xiaolian Zhang, 2016: Ficolin-2 binds to HIV-1 gp120 and blocks viral infection, Virologica Sinica, 31, 406-414. doi: 10.1007/s12250-016-3808-3
[2]
Minghui Li, Lu Zhang, Yao Lu, Qiqi Chen, Huihui Lu, Fangfang Sun, Zhan Zeng, Gang Wan, Linqing Zhao, Yao Xie, 2021: Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a, Virologica Sinica, 36, 311-320. doi: 10.1007/s12250-020-00290-7
[3]
Minghui Li, Fangfang Sun, Xiaoyue Bi, Yanjie Lin, Liu Yang, Yao Lu, Lu Zhang, Gang Wan, Wei Yi, Linqing Zhao, Yao Xie, 2022: Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients, Virologica Sinica, 37, 390-397. doi: 10.1016/j.virs.2022.03.001
[4]
Baoxin Zhao, Hongxiu Qiao, Yan Zhao, Zhiyun Gao, Weijie Wang, Yan Cui, Jian Li, Zhanjun Guo, Xia Chuai, Sandra Chiu, 2023: HBV precore G1896A mutation promotes growth of hepatocellular carcinoma cells by activating ERK/MAPK pathway, Virologica Sinica, 38, 680-689. doi: 10.1016/j.virs.2023.06.004
[5]
严亚琼, 陈冬峨, 曾艳彩, , , , 2004: Study on Risk Relationship between Hepatitis B Virus and Primary Hepatocellular Carcinoma, Virologica Sinica, 19, 549-552.
[6]
Yongjun Tian, Jing-hsiung James Ou, 2015: Genetic and epigenetic alterations in hepatitis B virus-associated hepatocellular carcinoma, Virologica Sinica, 30, 85-91. doi: 10.1007/s12250-015-3582-7
[7]
陈冬峨, 严亚琼, 曾艳彩, , , , 2004: The Relationship between Hepatocellular Cacinoma and Hepatitis B Virus Infection, Virologica Sinica, 19, 520-522.
[8]
王文亮王春杰师建国王冰枫, , , , 2001: Distribution and Significance of HCV and HBV Genes and Their Related Antigens in Hepatocellular Carcinoma, Virologica Sinica, 16, 325-329.
[9]
You-hua XIE, Ran HONG, Wei LIU, Jing LIU, Jian-wei ZHAI, 2010: Development of Novel Therapeutics for Chronic Hepatitis B^*, Virologica Sinica, 25, 294-300. doi: 10.1007/s12250-010-3138-9
[10]
巫振欧, 管美英, 林胜清, 吴章琦, 1987: EFFICACY OF HUMAN LEUKOCYTESINTERFERON IN CHRONIC HEPATITIS B, Virologica Sinica, 2, 45-.
[11]
方钟燎, 杨进业, 王学燕, 庄辉, Roger Ling, Tim J Harrison, 2000: The Discovery of HBV Core Tissue of Patients with Prom oter M Ⅱtations in Tum our Hepatocellular Carcinoma, Virologica Sinica, 15, 234-248.
[12]
Song Hu, Fahu Yuan, Lingyan Feng, Fang Zheng, Feili Gong, Hanju Huang, Binlian Sun, 2018: KIR2DL2/C1 is a Risk Factor for Chronic Infection and Associated with Non-response to PEG-IFN and RBV Combination Therapy in Hepatitis C Virus Genotype 1b Patients in China, Virologica Sinica, 33, 369-372. doi: 10.1007/s12250-018-0042-1
[13]
熊开钧, 黄华芳, 金慰鄂, 姚梦林, 曾令兰, 贺永文, 何生松, 吴章琦, 1986: THE INFLUENCE OF SMALL DOSAGES OF INTERFERON ON VIRUSES ON DIFFERENT STAGES OF CHRONIC HEPATITIS B, Virologica Sinica, 1, 24-.
[14]
黄华芳, 熊开钧, 何生松, 李瑗, 王萍, 蔡淑清, 曾令兰, 王心禾, 1991: The Observation on the Antiviral Effect of Ribavirin and Combining with Interferon in Patients with Chronic Hepatitis B, Virologica Sinica, 6, 201-.
[15]
熊开钧, 王心禾, 金慰鄂, 黄华芳, 姚梦林, 曾令兰, 韩才英, 范红梅, 吴章琦, 孙继山, 1986: EFFECT OF SMALL DOSAGE OF INTERFERON ON VIRAL MARKERS OF CHRONIC HEPATITIS B, Virologica Sinica, 1, 9-.
[16]
熊开钧, 王心禾, 黄华芳, 姚梦林, 金慰鄂, 曾令兰, 张雪珍, 1987: FOLLOW-UP OF CHRONIC HEPATITIS B TREATED WITH ACYCLOVIR, Virologica Sinica, 2, 18-.
[17]
吴国祥, 朱科青, 郑锦华, 1992: A Clinical Study on Anti--HBe Positive Chronic Hepatitis B, Virologica Sinica, 7, 22-.
[18]
Hongyan Liu, Jinlin Hou, Xiaoyong Zhang, 2018: Targeting cIAPs, a New Option for Functional Cure of Chronic Hepatitis B Infection?, Virologica Sinica, 33, 459-461. doi: 10.1007/s12250-018-0062-x
[19]
Jia Liu, Anna Kosinska, Mengji Lu, Michael Roggendorf, 2014: New therapeutic vaccination strategies for the treatment of chronic hepatitis B, Virologica Sinica, 29, 10-16. doi: 10.1007/s12250-014-3410-5
[20]
Pinghu Zhang, Shuo Zhai, Jinhong Chang, Ju-Tao Guo, 2018: In Vitro Anti-hepatitis B Virus Activity of 2', 3'-Dideoxyguanosine, Virologica Sinica, 33, 538-544. doi: 10.1007/s12250-018-0065-7